AI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live · FMP| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.11% | +1.10% | +4.46% | +22.87% | +16.24% | +12.16% | +4.28% | -12.20% | -0.26% | +197.51% | +1822.69% |
Aftermarket
Live · FMPLast trade
$389.12
297 sh
Bid
$378.47
10 sh
Ask
$396.77
2 sh
Spread
$18.300
Sector & industry today
Live · FMPSectors
- Basic Materials+1.50%
- Consumer Cyclical+1.07%
- Consumer Defensive+0.80%
- Industrials+0.09%
- Real Estate-0.38%
- Financial Services-0.43%
- Energy-0.89%
- Technology-0.89%
- Healthcare-1.37%
- Communication Services-1.47%
- Utilities-2.07%
Top industries (issuer's industry highlighted)
- Medical - Healthcare Plans+1.28%
- Software - Infrastructure+6.80%
- Broadcasting+4.85%
- Copper+4.82%
- Silver+4.70%
- Coal+4.65%
- Other Precious Metals+3.84%
- Renewable Utilities-2.84%
- Gold+2.80%
- Software - Application+2.71%
- Travel Lodging-2.70%
- Staffing & Employment Services+2.64%
Fair value
Football field →Weighted blend
$679.98
+72.94% vs spot
Recommendation
Strong Buy
20 of 21 methods
Method spread
10bull10bear
±5% threshold
Analyst PT consensus: $382.38 (-2.75%)
Total assets
$121.49B
Total debt
$33.24B
Cash & equiv
$9.49B
Operating CF
$4.29B
Free cash flow
$3.17B
Buybacks
-$2.61B
Analyst view
DB · price_targets + analyst_gradesConsensus target
$382.38
-2.75% upside
Low
$331.00
Median
$391.00
High
$425.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- A Look at Elevance Health Inc (ELV) After 4.0% Gain -- GF Value $518.29 vs Price $393.30gurufocus.com·May 12, 2026
- Is ELV Undervalued? DCF Says Worth $643gurufocus.com·May 12, 2026
- Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Carebusinesswire.com·May 04, 2026
- Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Carebusinesswire.com·May 04, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $50.18B | $1.76B | $8.00 |
| Q4 Dec 2025 | $49.75B | $547M | $2.47 |
| Q3 Sep 2025 | $50.71B | $1.19B | $5.32 |
| Q2 Jun 2025 | $49.78B | $1.74B | $7.72 |
| Q1 Mar 2025 | $48.89B | $2.18B | $9.61 |
| Q4 Dec 2024 | $45.44B | $418M | $1.81 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
SCHULMAN AMY W director | Sell | 26 | $7.48K | Mar 12, 2026 |
Kendrick Charles Morgan JR officer: EVP & President, Commercial | Sell | 3,196 | $910.6K | Mar 06, 2026 |
COLLIS STEVEN H director | Buy | 3,000 | $869.52K | Mar 05, 2026 |
DeVore Susan D. director | Buy | 1,200 | $374.58K | Aug 19, 2025 |
BOUDREAUX GAIL director, officer: President and CEO | Buy | 1,050 | $302.36K | Jul 18, 2025 |
BOUDREAUX GAIL director, officer: President and CEO | Buy | 2,334 | $667.69K | Jul 18, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $199.13B | $8.11B | $5.66B | $25.12 | +2.84% |
| FY 2024 | $176.81B | $8.89B | $5.98B | $25.68 | +3.38% |
| FY 2023 | $171.34B | $8.75B | $5.99B | $25.22 | +3.49% |
| FY 2022 | $156.6B | $8.45B | $5.89B | $24.28 | +3.76% |
| FY 2021 | $138.64B | $8.95B | $6.1B | $24.73 | +4.40% |